MYX Stock Overview
A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Mayne Pharma Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$4.18 |
| 52 Week High | AU$7.46 |
| 52 Week Low | AU$3.74 |
| Beta | 1.25 |
| 11 Month Change | -10.68% |
| 3 Month Change | -4.57% |
| 1 Year Change | -9.52% |
| 33 Year Change | -29.15% |
| 5 Year Change | -52.50% |
| Change since IPO | -65.17% |
Recent News & Updates
Recent updates
A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb
Sep 01
Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade
Mar 06Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers
Dec 03Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?
Dec 01Is Mayne Pharma Group (ASX:MYX) A Risky Investment?
Apr 12Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade
Mar 01We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope
Nov 16Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt
Nov 10Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt
May 17Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?
Mar 22How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?
Mar 01What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition
Feb 08Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit
Jan 18Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares
Dec 27Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?
Dec 09
A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation
Nov 24Shareholder Returns
| MYX | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -14.3% | -11.8% | 1.5% |
| 1Y | -9.5% | 39.8% | 17.2% |
Return vs Industry: MYX underperformed the Australian Pharmaceuticals industry which returned 39.8% over the past year.
Return vs Market: MYX underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| MYX volatility | |
|---|---|
| MYX Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: MYX has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: MYX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Shawn O’Brien | www.maynepharma.com |
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through three segments: Women’s Health, Dermatology, and International. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.
Mayne Pharma Group Limited Fundamentals Summary
| MYX fundamental statistics | |
|---|---|
| Market cap | AU$361.11m |
| Earnings (TTM) | -AU$168.62m |
| Revenue (TTM) | AU$388.40m |
0.9x
P/S Ratio-2.0x
P/E RatioIs MYX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYX income statement (TTM) | |
|---|---|
| Revenue | AU$388.40m |
| Cost of Revenue | AU$169.62m |
| Gross Profit | AU$218.78m |
| Other Expenses | AU$387.39m |
| Earnings | -AU$168.62m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.08 |
| Gross Margin | 56.33% |
| Net Profit Margin | -43.41% |
| Debt/Equity Ratio | 7.0% |
How did MYX perform over the long term?
See historical performance and comparison